Delivered-To: josh@josh.is
Received: by 2002:a2e:9802:0:0:0:0:0 with SMTP id a2csp5338413ljj;
        Tue, 7 Apr 2020 14:02:17 -0700 (PDT)
X-Received: by 2002:ac8:6686:: with SMTP id d6mr4324107qtp.149.1586293336920;
        Tue, 07 Apr 2020 14:02:16 -0700 (PDT)
ARC-Seal: i=1; a=rsa-sha256; t=1586293336; cv=none;
        d=google.com; s=arc-20160816;
        b=v64/DNRzkQMxbDL5U46dEOMsEWxxdW79NPyzHaJt/pb3MbwakWMfFXtttBwLi4mTHg
         5SsEoWqDBQbKU3FTw7/QuogwHaxwVj18vWjy9ttDmWXOfp4BEhilHKvbnUlOq5AsLaZL
         9AJENUBorZt6v2h1XEtRFfuB1nT6UJEbm58M/hYhsDTacopPUNlUd4Ufm//fdFs8/KlK
         kW9AaT6qeTNAXeN3ma+6PcFi6coCVsW7NJJnrB98S8it+lr1MdXt/rPB5wkPs0M63Em5
         6lowzj9vAJcKZXNTIal0/W5siXM0HOW+ZOz5z6s4bK5fXGZHQ+pBRNvdXVoEh7f83Euy
         ZCCw==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816;
        h=to:message-id:subject:date:mime-version:content-transfer-encoding
         :from:dkim-signature;
        bh=/ZfpnN4BmluPmPHoA7xyieyD6bwTC+nz/sQB0GuPOtE=;
        b=duEh1NxetXDJ2VzQG7Z3HeB7FDk7ijnfys2ltINBt5FKBJxXn6ZOgIOF1Qk3C3rSak
         RXQdKqdIv1U7nSZptRek2RH1H/nbr3gGQWktFhBiw2KbPras7H+MN3DL/jx6hlKdn/QJ
         Ewrq6wB3e3OuUsH8QRxf5EGCkgCDeHaho+/EL8LBa43ZrOxRxe2nJy+bgTladKPNpI4m
         wZ89R6mgrYa2VjA6k0pxSgSskmwpKNBskrgbsWTCJ+7AsaAjY8m0Fr8wV/h+/kLd5iQR
         9vD6ANCcOMCWmXpzGvP9bXi8hj2EnfAjOYI5SgAoLLEk+CYuxlqPOeMzL1q8eheteSAk
         ROow==
ARC-Authentication-Results: i=1; mx.google.com;
       dkim=pass header.i=@simple-is.20150623.gappssmtp.com header.s=20150623 header.b=lwCcn8hO;
       spf=neutral (google.com: 209.85.220.41 is neither permitted nor denied by best guess record for domain of hulda@simple.is) smtp.mailfrom=hulda@simple.is
Return-Path: <hulda@simple.is>
Received: from mail-sor-f41.google.com (mail-sor-f41.google.com. [209.85.220.41])
        by mx.google.com with SMTPS id n31sor5053549qva.35.2020.04.07.14.02.16
        for <josh@josh.is>
        (Google Transport Security);
        Tue, 07 Apr 2020 14:02:16 -0700 (PDT)
Received-SPF: neutral (google.com: 209.85.220.41 is neither permitted nor denied by best guess record for domain of hulda@simple.is) client-ip=209.85.220.41;
Authentication-Results: mx.google.com;
       dkim=pass header.i=@simple-is.20150623.gappssmtp.com header.s=20150623 header.b=lwCcn8hO;
       spf=neutral (google.com: 209.85.220.41 is neither permitted nor denied by best guess record for domain of hulda@simple.is) smtp.mailfrom=hulda@simple.is
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed;
        d=simple-is.20150623.gappssmtp.com; s=20150623;
        h=from:content-transfer-encoding:mime-version:date:subject:message-id
         :to;
        bh=/ZfpnN4BmluPmPHoA7xyieyD6bwTC+nz/sQB0GuPOtE=;
        b=lwCcn8hOmi09TLpxDftsw9ibAPZfdnvDtXMEedyz0RxcXvntNtVLceMIW9b8X/RLtA
         xjLip+d2bPdwaYYgY/LCHeH5+lhxYR6sSStphm+JalhXpogeMmb74/FWAxFPXRxsg+vp
         vF4wTIRJ7ppvERcPiCK8s/5PW6RpIoPM/W25IEQ19s/PXkiGbRQ5p6Kt8aFQpnotpH8r
         fCor/5Xc8qVeZc92lXeoxxxuQrdv579IOiqAcnRiH4ESKS5Vefm60ZP6/3PuoEjt16+a
         6AHuyELfyMn+uHDM1IKkZat73owWUKw2t4lb6WrVa/w1JCrTm4caCwoU3msAsYRG0sQW
         Pbag==
X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed;
        d=1e100.net; s=20161025;
        h=x-gm-message-state:from:content-transfer-encoding:mime-version:date
         :subject:message-id:to;
        bh=/ZfpnN4BmluPmPHoA7xyieyD6bwTC+nz/sQB0GuPOtE=;
        b=GS32KADQXpgycrjhZ7DGYcc0l/ZU1wdKxl3NleZbTu5TH6sB+sgSXYuKIRScIZdCqy
         1HSdEIMoHODtxz2DL5eeqeWs3F2MoXv9DUueVUQnH/yeHP0M9dQE/BqcJuL524+8nguQ
         jnx9Ee1Y+C6GEz0dnZtLrfAJI3eFPTxioM7Q+n2FYuhVnPaCZpIE9Na6ybh5Q+mt30H6
         dPKj+ovk7pLxVvnht4I5xh1iZfBL4PgDrKg8EiS+HImP9kYjeyQ6iFSOwoSSPW64VPAu
         0eUGGzyhqcPFlNZjVe7TaeJuLXA1rRbk0oP7ZT6MKtFkLUkl5sFMeBwAgGAx2uicfYnu
         JGYw==
X-Gm-Message-State: AGi0PuY2fgxivzgIT1DjJunYljfriunu+d6Z7pUNJzMbcxZ/g7FyMunl
	9aNPK9aAhAyMOwhBg1gXnkcB5f9fK44=
X-Google-Smtp-Source: APiQypJmAsXu2foElIkTOqY6DXYjeJlBpdsdkZlq0hLl724zgfWrQD4G2d56uxeXpbW3HaEv4ioBpg==
X-Received: by 2002:ad4:514d:: with SMTP id g13mr4168685qvq.229.1586293335747;
        Tue, 07 Apr 2020 14:02:15 -0700 (PDT)
Return-Path: <hulda@simple.is>
Received: from ?IPv6:2600:380:bd26:6285:2ca5:4866:55c5:969f? ([2600:380:bd26:6285:2ca5:4866:55c5:969f])
        by smtp.gmail.com with ESMTPSA id n92sm4748286qtd.68.2020.04.07.14.02.14
        for <josh@josh.is>
        (version=TLS1_3 cipher=TLS_AES_128_GCM_SHA256 bits=128/128);
        Tue, 07 Apr 2020 14:02:14 -0700 (PDT)
From: "Hulda@simple.is" <hulda@simple.is>
X-Google-Original-From: "Hulda@simple.is" <Hulda@simple.is>
Content-Type: multipart/alternative; boundary=Apple-Mail-6B09211F-79D0-405E-9344-0A28BBF95B12
Content-Transfer-Encoding: 7bit
Mime-Version: 1.0 (1.0)
Date: Tue, 7 Apr 2020 17:02:12 -0400
Subject: Business Insider: Coronavirus treatments: Most promising medical treatments for COVID-19
Message-Id: <3E29D5C6-0E25-49C2-AD2D-861321B66261@simple.is>
To: Josh Klein <josh@josh.is>
X-Mailer: iPhone Mail (17D50)


--Apple-Mail-6B09211F-79D0-405E-9344-0A28BBF95B12
Content-Type: text/plain;
	charset=us-ascii
Content-Transfer-Encoding: quoted-printable


Coronavirus treatments: Most promising medical treatments for COVID-19
There are no medical treatments for patients infected with the novel COVID-1=
9 virus. Some of the world's leading drugmakers are conducting trials on can=
didate drugs like remdesivir and Actemra. Business Insider has compiled a li=
st of the most promising coronavirus medical treatments undergoing clinical t=
esting. Visit Business Insider's homepage for more stories.

Read in Business Insider: https://apple.news/AVFwyIh7_SKaLylI2v0mzpg


Shared from Apple News

--Apple-Mail-6B09211F-79D0-405E-9344-0A28BBF95B12
Content-Type: text/html;
	charset=utf-8
Content-Transfer-Encoding: 7bit

<html><head><meta http-equiv="content-type" content="text/html; charset=utf-8"></head><body dir="auto"><div dir="ltr"><br><strong>Coronavirus treatments: Most promising medical treatments for COVID-19</strong><br>There are no medical treatments for patients infected with the novel COVID-19 virus. Some of the world's leading drugmakers are conducting trials on candidate drugs like remdesivir and Actemra. Business Insider has compiled a list of the most promising coronavirus medical treatments undergoing clinical testing. Visit Business Insider's homepage for more stories.<br><br>Read in  Business Insider: <a href="https://apple.news/AVFwyIh7_SKaLylI2v0mzpg">https://apple.news/AVFwyIh7_SKaLylI2v0mzpg</a><br><br><br>Shared from <a href="https://www.apple.com/news">Apple News</a><br></div></body></html>
--Apple-Mail-6B09211F-79D0-405E-9344-0A28BBF95B12--
